
Angela A. Armstrong
Examiner (ID: 7226, Phone: (571)272-7598 , Office: P/2659 )
| Most Active Art Unit | 2659 |
| Art Unit(s) | 2659, 2641, 2741, 2654, 2626 |
| Total Applications | 1003 |
| Issued Applications | 675 |
| Pending Applications | 123 |
| Abandoned Applications | 230 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 5959665
[patent_doc_number] => 20110184052
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2011-07-28
[patent_title] => 'ARGINASE II: A TARGET FOR THE PREVENTION AND TREATMENT OF ATHEROSCLEROSIS'
[patent_app_type] => utility
[patent_app_number] => 12/975136
[patent_app_country] => US
[patent_app_date] => 2010-12-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 14
[patent_figures_cnt] => 14
[patent_no_of_words] => 16804
[patent_no_of_claims] => 27
[patent_no_of_ind_claims] => 16
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0184/20110184052.pdf
[firstpage_image] =>[orig_patent_app_number] => 12975136
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/975136 | ARGINASE II: A TARGET FOR THE PREVENTION AND TREATMENT OF ATHEROSCLEROSIS | Dec 20, 2010 | Abandoned |
Array
(
[id] => 6046582
[patent_doc_number] => 20110206648
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2011-08-25
[patent_title] => 'Gene-enhanced tissue engineering'
[patent_app_type] => utility
[patent_app_number] => 12/928805
[patent_app_country] => US
[patent_app_date] => 2010-12-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 9
[patent_no_of_words] => 18621
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0206/20110206648.pdf
[firstpage_image] =>[orig_patent_app_number] => 12928805
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/928805 | Gene-enhanced tissue engineering | Dec 19, 2010 | Abandoned |
Array
(
[id] => 6090348
[patent_doc_number] => 20110218144
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2011-09-08
[patent_title] => 'Method of Reducing Deleterious Effects of Ischemia-Reperfusion'
[patent_app_type] => utility
[patent_app_number] => 12/971678
[patent_app_country] => US
[patent_app_date] => 2010-12-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 13
[patent_figures_cnt] => 13
[patent_no_of_words] => 10542
[patent_no_of_claims] => 11
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0218/20110218144.pdf
[firstpage_image] =>[orig_patent_app_number] => 12971678
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/971678 | Method of reducing deleterious effects of ischemia by administration of a thrombopoietin receptor ligand | Dec 16, 2010 | Issued |
Array
(
[id] => 6039493
[patent_doc_number] => 20110092542
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2011-04-21
[patent_title] => 'METHODS FOR TREATING SPINAL CORD INJURY WITH A COMPOUND THAT INHIBITS A NCCA-ATP CHANNEL'
[patent_app_type] => utility
[patent_app_number] => 12/964018
[patent_app_country] => US
[patent_app_date] => 2010-12-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 18
[patent_figures_cnt] => 18
[patent_no_of_words] => 24801
[patent_no_of_claims] => 14
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0092/20110092542.pdf
[firstpage_image] =>[orig_patent_app_number] => 12964018
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/964018 | Methods for treating spinal cord injury with a compound that inhibits a NCCA-ATP channel | Dec 8, 2010 | Issued |
Array
(
[id] => 8201697
[patent_doc_number] => 08188248
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2012-05-29
[patent_title] => 'Nucleic acids encoding interleukin-12P40 variants with improved stability'
[patent_app_type] => utility
[patent_app_number] => 12/961733
[patent_app_country] => US
[patent_app_date] => 2010-12-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 17
[patent_figures_cnt] => 31
[patent_no_of_words] => 9920
[patent_no_of_claims] => 32
[patent_no_of_ind_claims] => 5
[patent_words_short_claim] => 51
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/08/188/08188248.pdf
[firstpage_image] =>[orig_patent_app_number] => 12961733
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/961733 | Nucleic acids encoding interleukin-12P40 variants with improved stability | Dec 6, 2010 | Issued |
Array
(
[id] => 8245042
[patent_doc_number] => 08202969
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2012-06-19
[patent_title] => 'Platelet derived growth factor receptor alpha (PDGFRA) polypeptides comprising activating mutation(s)'
[patent_app_type] => utility
[patent_app_number] => 12/959588
[patent_app_country] => US
[patent_app_date] => 2010-12-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 12
[patent_no_of_words] => 28506
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 96
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/08/202/08202969.pdf
[firstpage_image] =>[orig_patent_app_number] => 12959588
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/959588 | Platelet derived growth factor receptor alpha (PDGFRA) polypeptides comprising activating mutation(s) | Dec 2, 2010 | Issued |
Array
(
[id] => 6039381
[patent_doc_number] => 20110092430
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2011-04-21
[patent_title] => 'METHOD AND COMPOUND FOR THE TREATMENT OF VALVULAR DISEASE'
[patent_app_type] => utility
[patent_app_number] => 12/956615
[patent_app_country] => US
[patent_app_date] => 2010-11-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 4
[patent_no_of_words] => 10189
[patent_no_of_claims] => 49
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0092/20110092430.pdf
[firstpage_image] =>[orig_patent_app_number] => 12956615
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/956615 | METHOD AND COMPOUND FOR THE TREATMENT OF VALVULAR DISEASE | Nov 29, 2010 | Abandoned |
Array
(
[id] => 8522232
[patent_doc_number] => 20120321640
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2012-12-20
[patent_title] => 'VON WILLEBRAND FACTOR SPECIFIC BINDING AGENTS AND USES THEREOF'
[patent_app_type] => utility
[patent_app_number] => 13/512126
[patent_app_country] => US
[patent_app_date] => 2010-11-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 11
[patent_no_of_words] => 17736
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13512126
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/512126 | VON WILLEBRAND FACTOR SPECIFIC BINDING AGENTS AND USES THEREOF | Nov 24, 2010 | Abandoned |
Array
(
[id] => 6062186
[patent_doc_number] => 20110200605
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2011-08-18
[patent_title] => 'Polypeptides and use thereof'
[patent_app_type] => utility
[patent_app_number] => 12/952869
[patent_app_country] => US
[patent_app_date] => 2010-11-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 17
[patent_figures_cnt] => 17
[patent_no_of_words] => 11123
[patent_no_of_claims] => 28
[patent_no_of_ind_claims] => 9
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0200/20110200605.pdf
[firstpage_image] =>[orig_patent_app_number] => 12952869
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/952869 | Polypeptides and use thereof | Nov 22, 2010 | Abandoned |
Array
(
[id] => 8393174
[patent_doc_number] => 20120231006
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2012-09-13
[patent_title] => 'ANTI-ORAI1 ANTIGEN BINDING PROTEINS AND USES THEREOF'
[patent_app_type] => utility
[patent_app_number] => 13/510926
[patent_app_country] => US
[patent_app_date] => 2010-11-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 55
[patent_figures_cnt] => 55
[patent_no_of_words] => 80276
[patent_no_of_claims] => 37
[patent_no_of_ind_claims] => 6
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13510926
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/510926 | ANTI-ORAI1 ANTIGEN BINDING PROTEINS AND USES THEREOF | Nov 18, 2010 | Abandoned |
Array
(
[id] => 8648769
[patent_doc_number] => 20130034499
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2013-02-07
[patent_title] => 'SGII AS A PROGNOSTIC MARKER IN CONDITIONS WHICH REQUIRE CRITICAL CARE'
[patent_app_type] => utility
[patent_app_number] => 13/508798
[patent_app_country] => US
[patent_app_date] => 2010-11-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 9
[patent_no_of_words] => 17491
[patent_no_of_claims] => 25
[patent_no_of_ind_claims] => 5
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13508798
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/508798 | SGII AS A PROGNOSTIC MARKER IN CONDITIONS WHICH REQUIRE CRITICAL CARE | Nov 14, 2010 | Abandoned |
Array
(
[id] => 6071501
[patent_doc_number] => 20110046352
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2011-02-24
[patent_title] => 'DISEASE-RESISTANT PLANTS AND METHOD OF CONSTRUCTING THE SAME'
[patent_app_type] => utility
[patent_app_number] => 12/938645
[patent_app_country] => US
[patent_app_date] => 2010-11-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 4
[patent_no_of_words] => 10120
[patent_no_of_claims] => 1
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0046/20110046352.pdf
[firstpage_image] =>[orig_patent_app_number] => 12938645
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/938645 | DISEASE-RESISTANT PLANTS AND METHOD OF CONSTRUCTING THE SAME | Nov 2, 2010 | Abandoned |
Array
(
[id] => 7696222
[patent_doc_number] => 20110230368
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2011-09-22
[patent_title] => 'High Throughput Assays for TRPM7'
[patent_app_type] => utility
[patent_app_number] => 12/916222
[patent_app_country] => US
[patent_app_date] => 2010-10-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 10
[patent_figures_cnt] => 10
[patent_no_of_words] => 9465
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0230/20110230368.pdf
[firstpage_image] =>[orig_patent_app_number] => 12916222
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/916222 | High Throughput Assays for TRPM7 | Oct 28, 2010 | Abandoned |
Array
(
[id] => 8968622
[patent_doc_number] => 08507433
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2013-08-13
[patent_title] => 'Cardioprotective effects of GHRH agonists'
[patent_app_type] => utility
[patent_app_number] => 12/914023
[patent_app_country] => US
[patent_app_date] => 2010-10-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 11
[patent_no_of_words] => 7608
[patent_no_of_claims] => 2
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 41
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12914023
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/914023 | Cardioprotective effects of GHRH agonists | Oct 27, 2010 | Issued |
Array
(
[id] => 8358634
[patent_doc_number] => 20120213798
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2012-08-23
[patent_title] => 'METHODS AND USES FOR TREATING HEPATIC ISCHEMIA AND REPERFUSION INJURY'
[patent_app_type] => utility
[patent_app_number] => 13/504021
[patent_app_country] => US
[patent_app_date] => 2010-10-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 9
[patent_no_of_words] => 12326
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 5
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13504021
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/504021 | METHODS AND USES FOR TREATING HEPATIC ISCHEMIA AND REPERFUSION INJURY | Oct 26, 2010 | Abandoned |
Array
(
[id] => 8465625
[patent_doc_number] => 20120270793
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2012-10-25
[patent_title] => 'METHODS OF TREATING A PATIENT RECEIVING A CARDIAC STENT IMPLANT'
[patent_app_type] => utility
[patent_app_number] => 13/496408
[patent_app_country] => US
[patent_app_date] => 2010-10-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 4
[patent_no_of_words] => 12583
[patent_no_of_claims] => 51
[patent_no_of_ind_claims] => 10
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13496408
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/496408 | METHODS OF TREATING A PATIENT RECEIVING A CARDIAC STENT IMPLANT | Oct 20, 2010 | Abandoned |
Array
(
[id] => 6000736
[patent_doc_number] => 20110117113
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2011-05-19
[patent_title] => 'IMMUNOGLOBULIN SINGLE VARIABLE DOMAIN DIRECTED AGAINST HUMAN CXCR4 AND OTHER CELL ASSOCIATED PROTEINS AND METHODS TO GENERATE THEM'
[patent_app_type] => utility
[patent_app_number] => 12/897051
[patent_app_country] => US
[patent_app_date] => 2010-10-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 3
[patent_no_of_words] => 28527
[patent_no_of_claims] => 26
[patent_no_of_ind_claims] => 10
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0117/20110117113.pdf
[firstpage_image] =>[orig_patent_app_number] => 12897051
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/897051 | IMMUNOGLOBULIN SINGLE VARIABLE DOMAIN DIRECTED AGAINST HUMAN CXCR4 AND OTHER CELL ASSOCIATED PROTEINS AND METHODS TO GENERATE THEM | Oct 3, 2010 | Abandoned |
Array
(
[id] => 6503419
[patent_doc_number] => 20100286381
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2010-11-11
[patent_title] => 'DIAGNOSTIC METHOD FOR CANCER CHARACTERIZED IN THE DETECTION OF THE DELETION OF G-CSF EXON 3'
[patent_app_type] => utility
[patent_app_number] => 12/830085
[patent_app_country] => US
[patent_app_date] => 2010-07-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 16
[patent_figures_cnt] => 16
[patent_no_of_words] => 10449
[patent_no_of_claims] => 2
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0286/20100286381.pdf
[firstpage_image] =>[orig_patent_app_number] => 12830085
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/830085 | DIAGNOSTIC METHOD FOR CANCER CHARACTERIZED IN THE DETECTION OF THE DELETION OF G-CSF EXON 3 | Jul 1, 2010 | Abandoned |
Array
(
[id] => 6177406
[patent_doc_number] => 20110178015
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2011-07-21
[patent_title] => 'METHODS OF TREATMENT USING BIASED LIGANDS FOR RECEPTORS SUCH AS THE PTH RECEPTOR'
[patent_app_type] => utility
[patent_app_number] => 12/829171
[patent_app_country] => US
[patent_app_date] => 2010-07-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 8
[patent_no_of_words] => 32622
[patent_no_of_claims] => 29
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0178/20110178015.pdf
[firstpage_image] =>[orig_patent_app_number] => 12829171
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/829171 | METHODS OF TREATMENT USING BIASED LIGANDS FOR RECEPTORS SUCH AS THE PTH RECEPTOR | Jun 30, 2010 | Abandoned |
Array
(
[id] => 10115771
[patent_doc_number] => 09150642
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2015-10-06
[patent_title] => 'Anti-KTPAF50 antibodies and their uses in therapeutic and diagnostic methods'
[patent_app_type] => utility
[patent_app_number] => 13/380605
[patent_app_country] => US
[patent_app_date] => 2010-06-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 19
[patent_figures_cnt] => 38
[patent_no_of_words] => 20912
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 51
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13380605
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/380605 | Anti-KTPAF50 antibodies and their uses in therapeutic and diagnostic methods | Jun 28, 2010 | Issued |